ICC Wants Only 10 Teams In World Cup SPFL Accused Of Underselling TV Rights Williams F1 Team Partners With BT British Masters Returns To European Tour Celtic Reportedly Signs New Balance Deal Llambias, Leach Stall Rangers Takeover Four São Paulo Athletic Clubs Receive $2M Royal St. George's To Allow Women League Notes NRL Forced To Backflip On Power Grab
Enter amount in full numerical value, without currency symbol or commas (ex: 3000000).
Upcoming Conferences and Events
SBD Global/July 3, 2013/Leagues and Governing Bodies
Pirelli Strengthens Tires For Nürburgring Race After Blowouts At British F1 Grand Prix
Published July 3, 2013
ECCLESTONE TO GERMANY: Also in London, Kevin Eason reported F1 CEO Bernie Ecclestone "will travel to the German Grand Prix to head off the threat of rebellion among Formula One’s teams and drivers even though he risks facing a damaging legal action." Ecclestone "still has the prospect of bribery charges hanging over him." The 82-year-old said that he "does not fear travelling to the Nürburgring and is anxious to make sure the race goes ahead safely without a repeat of the exploding Pirelli tyres that almost marred the British Grand Prix at the weekend." Ecclestone said, "I will definitely be going to Germany. I just hope I will be coming back" (LONDON TIMES, 7/2).
PIRELLI BLAMES TEAMS: In London, Ian Parkes wrote the tiremaker "has risked incurring the wrath of Formula One's teams by claiming they are primarily to blame for the high-speed tyre explosions." Pirelli said that after "exhaustive analysis" of the Silverstone failures that occurred at Silverstone, its tires "are safe, if used correctly." Pirelli said that there are four factors behind the failures: "the incorrect reverse mounting of the rear tyres; adoption by the teams of too-low pressures; extreme camber settings; and aggressive kerbing at Silverstone." Pirelli claims that its rear tires "are not designed to be interchangeable," and under-inflation and extreme cambers "can be dangerous under certain circumstances" (INDEPENDENT, 7/2).